The report’s pricing estimates concern annual net prices for drugs included in the analysis and describe the launch-year market rather than the subsequent evolution of each product’s price. About one in four drugs introduced in 2025 had an annual net price exceeding $500,000. A further 34% were launched at prices between $200,000 and $500,000. Taken together, those categories show that more than half of the 2025 launches in the report had annual net prices of at least $200,000, while a substantial minority exceeded half a million dollars per year.

ICER also compared launch prices with its recommended price benchmarks for newly approved drugs that the institute had previously reviewed. In that subset, only about one-third of the medicines were priced at or below the relevant benchmark; the remainder exceeded ICER’s estimated value. This comparison applied only to drugs for which ICER had completed a review and established a benchmark. It did not demonstrate that price differences caused lower use, poorer adherence or worse clinical outcomes, and the release did not provide a count of the medicines in this subset.

Patient access was also assessed during the first year after approval. Among the outpatient prescriptions examined, only one-third were ultimately filled within 30 days of a patient attempting to fill them. A significant proportion of prescriptions were rejected because the medicine was not covered, with new-to-market coverage blocks identified as a likely contributor. The finding therefore describes the early post-approval experience for the outpatient prescriptions included in the analysis, rather than every prescription written, filled or experienced by patients during that period.

The report’s leaders characterized high launch prices and uneven access as major barriers across the US health system. Sarah K. Emond, president and CEO of ICER, said that overpayment for drugs beyond their value to patients is contributing to decreased access and called for fair pricing to be paired with fair access. Timothy Lash, president and chair of the West Health Policy Center, said many Americans were struggling to obtain needed prescription medicines and that higher prices can force difficult tradeoffs for seniors living on fixed incomes. These statements represented the organizations’ interpretation of the report’s findings and policy priorities.

Medicare beneficiaries experienced higher rates of coverage rejection than patients covered by other payer types, according to the report’s access findings. Lash said this pattern made the burden of high launch prices especially stark for Medicare recipients, noting that beneficiaries who did obtain access could still face higher costs. Because the analysis covered the first year after approval and included both filled and rejected outpatient prescriptions, the results offer a view of early access after a drug’s launch. They do not represent a count of all patients who eventually received treatment.

Separate survey findings released with the report showed widespread concern about affordability. In July 2026, nearly 40% of Americans surveyed by the West Health-Gallup Center for Healthcare said they were concerned or very concerned that their household would be unable to pay for needed prescription drugs during the following 12 months. That share was up from 25% in July 2022. Concern was also more pronounced among respondents with multiple health conditions: 49% of people with three or more chronic conditions expressed concern or very concern, compared with 36% of adults aged 65 and older.

The launch-price analysis followed a protocol ICER announced in May 2026. ICER identified IPD Analytics and IQVIA as data partners and collaborated with the National Health Council on patient engagement. The report deliberately centered net prices because earlier drug-pricing analyses had often concentrated on public list prices, which do not always equal the price paid after rebates and discounts. Its access component added a prescription-level view by tracking whether attempts to obtain outpatient medicines succeeded within 30 days after launch, including the role of coverage rejections.

The available release does not detail the number of drugs represented in every pricing category or the number of outpatient prescriptions examined in the access analysis. Its scope also centers on selected US launches, the comparison of medicines previously reviewed by ICER, and access during the first year after approval. As a result, the findings should not be treated as a direct measurement of every segment of the US drug market or as evidence about long-term patient outcomes. They instead show how the median real net launch price changed over the reported period, how prices were distributed among recent launches, and how often the outpatient prescriptions studied were filled promptly or rejected because of lack of coverage.

ICER scheduled a public webinar for October 27, 2026, at noon Eastern Time to discuss rising launch prices and their implications for affordability and access. Foluso Agboola, senior vice president of research at ICER, was to present the report’s main findings before a panel discussion moderated by Emond. The announced panel included Rebecca Kirch of the National Patient Advocate Foundation, Magda Rusinowski of the Business Group on Health, and Namrata Kaur Uberoi of West Health. Taken together, the report found that the median net launch price reached $257,000 in 2025, many launches carried annual prices in the hundreds of thousands of dollars, only about one-third of newly approved medicines previously reviewed by ICER met its recommended price benchmark, and just one-third of the outpatient prescriptions studied were filled within 30 days of the initial attempt.

Subject of Research: US prescription drug launch prices and early outpatient access

Article Title: ICER, West Health releases new report indicating that median prices of newly launched drugs continue to exceed $250,000

Article References: ICER, West Health releases new report indicating that median prices of newly launched drugs continue to exceed $250,000. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: drug launch prices, net prices, prescription drugs, patient access, coverage rejections, Medicare, health affordability, ICER, West Health, prescription fulfillment, West, Health

The research team, led by pharmacist and PhD researcher Beatriz Santos, interviewed 30 ambulatory patients in Geneva, Switzerland, between July and December 2022, ultimately analyzing the accounts of 24 adults living with chronic conditions such as diabetes, hypertension, and respiratory disease. To be included, participants had to have been on a prescribed medication for at least six months and to have modified their intake at least once in the previous year without consulting a healthcare professional first. The interviews, conducted in French and lasting an average of 35 minutes, were transcribed, verified, and analyzed using a low-inference qualitative descriptive approach with MAXQDA software, a method chosen to stay as close as possible to participants’ own words rather than imposing heavy theoretical interpretation. Recruitment deliberately avoided stigmatizing language such as “non-adherent,” a choice the researchers say was essential for getting people to open up about behavior they often keep hidden.

What emerged was a wide repertoire of adjustment techniques. Participants reported skipping or reducing doses, temporarily interrupting treatment, splitting a single daily dose across the day, altering the timing of intake, and replacing pharmaceutical products with non-pharmacological alternatives. The medications involved ranged from preventive therapies such as antihypertensives, metformin, calcium, and vitamin supplements to insulin and other diabetes treatments. Notably, the researchers encouraged participants to discuss all of their medications, not just those for the conditions they were recruited through, reflecting the multimorbid reality of most chronic patients, who in this study carried an average of 2.3 chronic conditions each.

Perhaps the most striking finding is what the researchers call using the body as a compass. Many participants described relying on physical sensations, symptoms, or intuition as their primary guide for deciding when and how much medication to take, sometimes explicitly prioritizing these bodily signals over medical advice. One participant explained how leg pain served as a rough glucose meter, allowing him to estimate his blood sugar from where the pain stopped in his leg. Another insisted on the right to test things personally, saying that even if the diabetologist had insisted on a dose, he wanted first to see what was happening inside his own body, because, as he put it, it is his body and it belongs to him. The researchers interpret this as a form of experiential knowledge: rather than passively following prescriptions, these patients engage in dynamic self-monitoring, tailoring treatment to perceived needs through observation, trial, and error.

Interestingly, this bodily compass can be partly displaced by technology. Several participants described how monitoring devices, such as continuous glucose sensors or home blood pressure monitors, shifted their adjustment decisions from subjective feelings toward objective numbers. One participant reported interrupting insulin for the exact number of days her glucose sensor was removed, since without the device she could not measure her blood sugar at all. Another began checking her blood pressure at home and skipping her telmisartan whenever the reading was low, replacing a vague sense of fatigue-driven guessing with a numeric threshold. The authors note a double edge here: as patients delegate self-monitoring to devices, they may become less attuned to their own symptoms, creating a potential vulnerability whenever access to the technology is interrupted.

Why do patients do this? The dominant driver, the study found, is a perceived lack of need or benefit. Consistent with the Health Belief Model, a well-established psychological framework linking health behavior to perceived susceptibility, severity, benefits, and barriers, participants who felt no symptoms, particularly those on preventive treatments for osteoporosis or hypertension, struggled to see the point of daily pills. Some substituted what they considered natural equivalents: eating more Parmesan cheese for iron, drinking orange juice for vitamin D, or relying on dairy products instead of calcium supplements, occasionally with visible confusion between vitamins. Others adjusted to cope with medication overload, with one participant joking that the pile of pills she took daily could almost be spread on toast. Practical barriers mattered too: injections that hurt, pills too large to swallow discreetly in restaurants, side effects that ruined holidays, demanding work weeks in which a hypoglycemic episode felt unmanageable, and even insurance reimbursement limits that pushed one patient to plan dose reductions toward the end of the year.

Beneath these practical calculations lies a hidden hierarchy. Participants consistently ranked their medications, treating some as untouchable and others as negotiable. Long-standing treatments, woven into habit and routine, were considered more important and less likely to be adjusted, while newer additions, supplements, and preventive therapies sat lower on the ladder. The clinical context of prescription also weighed heavily: medications initiated after frightening events, such as a minor stroke, were regarded as essential, with one participant singling out her aspirin as non-negotiable for precisely that reason. The researchers argue that recognizing this patient-constructed frame of reference, which may diverge sharply from clinical priorities, is essential for any realistic conversation about adherence.

The emotional texture of self-adjustment is ambivalent. Participants described feelings of freedom, control, and empowerment, a sense of being the true experts on their own conditions, with one declaring that the patient is their best doctor. Yet the same decisions frequently produced guilt, anxiety, and an internal conflict that made medication management painful. One participant described the liberation of deciding not to take a pill, immediately followed by the recognition that she was not really free, because she knew she was doing something not right for her health. Fear of judgment kept many from disclosing these behaviors to prescribers, with some preferring to let six-monthly blood tests reveal the truth rather than face a lecture. Where physicians responded rigidly, patients described feeling like scolded schoolchildren and reluctantly resuming treatment; where physicians validated their reasoning, patients reported strengthened autonomy and a more honest relationship.

The study’s authors, whose protocol was approved by the Geneva Regional Research Ethics Committee and whose recruitment spanned pharmacies, hospital outpatient clinics, primary care centers, and patient associations, are careful about the limits of their work. Participants were highly educated, all came from a single French-speaking canton, and those willing to discuss such sensitive behavior may differ from those who are not. Still, the team reached thematic saturation, with later interviews generating no new insights, and they argue the descriptive foundation now justifies quantitative research into how common specific adjustment behaviors are and how they affect clinical outcomes. Their prescription for change is clear: patients need safer, more informed pathways to do what many are already doing anyway. That means patient education programs on medication adjustment, collaborative care frameworks, and above all a shift from directive, one-size-fits-all prescribing toward genuine dialogue in which patients feel heard, respected, and able to experiment openly with their clinicians rather than in secret. As the authors conclude, acknowledging both the clinician’s expertise and the patient’s agency may be the only way to close the gap between what is prescribed and what is actually taken.

Subject of Research: Patient self-adjustment of long-term medication regimens without consulting healthcare providers

Article Title: Self-Adjusting Long-Term Medications: A Qualitative Descriptive Study of Patients’ Practices

Article References: Santos, B., Arnoux, S., Pechère-Bertschi, A., Empeyta, S., Hudelson, P., & Schneider, M. (2026). Self-Adjusting Long-Term Medications: A Qualitative Descriptive Study of Patients’ Practices. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10842-4

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10842-4

Keywords: medication adherence, self-adjustment, chronic disease, qualitative research, patient-provider communication, diabetes, hypertension, Health Belief Model, self-management, patient education, shared decision-making, prescription drugs

The study, led by Clement P. Buclin of Geneva University Hospitals and the University of Geneva together with colleagues across Swiss and Canadian institutions, was conducted between March and June 2025. The researchers embedded questions on GLP-1 receptor agonist use into an omnibus survey run with the Swiss Federal Office for Statistics, using a probabilistic sampling design so that the 5,818 respondents surveyed could be weighted to represent 7.43 million individuals nationwide. This approach matters because most existing evidence on GLP-1 uptake comes from prescription databases or insurance claims, which capture only the formal, physician-mediated pathway. By asking people directly, the team could detect use that never appears in any pharmacy record, including medications bought abroad, obtained through informal networks, or shared within households.

The headline prevalence figure of 2.5 percent, with a 95 percent confidence interval of 2.1 to 3.0 percent, may sound modest, but it translates into a substantial population burden for a drug class that requires ongoing injections, careful dose titration, and monitoring for gastrointestinal and other adverse effects. Semaglutide emerged as the most frequently reported agent, consistent with its dominance in both diabetes and obesity treatment guidelines and its outsized presence in public discourse. The finding that weight loss, rather than glycemic control, was the primary indication among most users underscores how thoroughly these agents have been repositioned in the public mind from diabetes drugs to lifestyle medications, a shift that regulators and clinicians are still catching up with.

Statistically, the survey revealed that use was strongly patterned by body size and, intriguingly, by perceived weight status. In multivariable models adjusting for other factors, participants reporting important overweight had nearly seven times the odds of using a GLP-1 receptor agonist compared with those reporting normal weight, with an odds ratio of 6.94 and a confidence interval of 3.01 to 16.02. Among those with a body mass index of 35 kilograms per square meter or higher, the odds ratio climbed to 8.54, with a confidence interval of 4.34 to 16.81. These gradients are exactly what clinical guidelines would predict, since obesity indications are typically reserved for people with a BMI of 30 or above, or 27 and above with weight-related comorbidities. The fact that the observed association tracks BMI so cleanly suggests that, at the population level, the drugs are at least reaching the populations for which they were designed.

One of the more unexpected results concerned gender. Despite the intense marketing of these drugs toward women in popular media, and despite women’s generally higher engagement with weight-loss interventions, the survey found no independent association between gender and GLP-1 receptor agonist use once age, BMI category, and self-reported weight status were accounted for. Age, by contrast, was independently associated with use, with the relationship varying across the lifespan in ways the authors suggest reflect both the epidemiology of obesity and prescribing caution in older adults. This dissociation between perceived demand and actual use patterns is a useful corrective to anecdotal impressions and highlights why representative surveys remain indispensable even in an era of big prescription data.

The most policy-relevant finding, however, lies in the informal access pathway. Among users, 7.3 percent reported obtaining the medication at least once outside physician-led prescribing pathways, or passing it forwards to family and friends. Weighted to the national level, that corresponds to more than 13,500 individuals in Switzerland. In practical terms, this means vials and pens intended for a single named patient are being split, lent, or sold within social networks, a practice with real pharmacological consequences. GLP-1 receptor agonists require individualized dose escalation, screening for contraindications such as personal or family history of medullary thyroid carcinoma or pancreatitis, and monitoring for red-flag symptoms. A medication borrowed from a friend arrives with none of that scaffolding, and the person receiving it may not even know the correct injection technique or storage requirements.

Perhaps most telling is who these informal users are. The study found that people reporting informal access were younger, more likely to be single, and more likely to report normal weight than formal-pathway users. That profile, young, socially connected, and not meeting conventional obesity thresholds, paints a picture of cosmetic or preventive use flowing through peer networks rather than medical channels. It also raises the possibility that informal access functions as a workaround for people who cannot obtain a prescription because they do not meet clinical criteria, or who face cost barriers, waiting lists, or reluctance to discuss weight with a physician. Whatever the mechanism, the direction is clear: the tighter the formal gatekeeping, the greater the incentive to find the drug elsewhere, and the younger the population doing so.

The clinical implications extend beyond Switzerland. Semaglutide and related agents such as tirzepatide act on the GLP-1 receptor to slow gastric emptying, enhance satiety, and improve insulin secretion in a glucose-dependent manner, effects that translate into substantial average weight reductions in trials but also into nausea, vomiting, and, rarely, more serious events such as pancreatitis and gallbladder disease. Discontinuation typically leads to weight regain, meaning these are long-term therapies, not short courses. When use migrates into informal channels, the risks multiply: no baseline assessment, no titration schedule, no adverse-event reporting, and no mechanism for detecting counterfeit or improperly stored products. Regulators across Europe and North America have already warned about compounded and counterfeit semaglutide circulating outside legitimate supply chains, and the Swiss data provide a quantitative estimate of how much informal circulation may underlie those warnings.

The authors argue that informal access among younger adults with lower BMI warrants both clinical and policy attention, and the survey gives policymakers a baseline against which future interventions can be measured. Possible responses include clearer public communication about who benefits from these drugs and who does not, tighter stewardship of the supply chain, and better access to structured obesity care so that patients are not pushed toward informal sources by default. The study also demonstrates the value of the omnibus survey model: by piggybacking a small set of well-designed items onto an existing national survey, the team produced actionable prevalence estimates at modest cost, funded by the Department of Medicine at Geneva University Hospitals, with no role for the funder in design, analysis, or reporting.

As GLP-1 receptor agonists continue their march from specialty clinics into everyday life, the Swiss survey offers a template for surveillance that other countries would do well to copy. It quantifies not just how many people use these drugs, but who uses them, why, and through which channels, revealing a hidden layer of informal circulation concentrated among the young and the slim. If the global trajectory of these medications mirrors what Switzerland is already experiencing, the coming years will see informal access grow alongside legitimate prescribing, and health systems will need data of exactly this kind to keep the balance between access and safety. For now, the message is sobering: the Ozempic era is not only bigger than prescription records suggest, it is also less visible, less supervised, and younger than most clinicians might assume.

Subject of Research: Population-level use and informal access pathways of GLP-1 receptor agonists in Switzerland

Article Title: Use and informal access to GLP-1 receptor agonists in Switzerland: a national survey

Article References: Buclin, C. P., Bonnet, R., Mongin, D., de Marcos, L., Reny, J.-L., Agoritsas, T., & Courvoisier, D. S. (2026). Use and informal access to GLP-1 receptor agonists in Switzerland: a national survey. BMC Medicine. https://doi.org/10.1186/s12916-026-05206-y

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05206-y

Keywords: GLP-1 receptor agonists, semaglutide, obesity, weight loss, Switzerland, national survey, informal access, prescription drugs, self-medication, BMI, public health, drug safety

The research, published in the International Journal of Obesity, exploits one of the distinctive strengths of the Nordic research infrastructure. In Finland, comprehensive national registers record prescription drug purchases, healthcare utilization, education, income, employment status, family structure and place of residence for virtually the entire population. By linking these registers at the individual level, researchers can assemble an exceptionally complete picture of medication use across society, free from the recall bias, volunteer bias and loss to follow-up that plague conventional surveys. This makes register studies of this kind uniquely suited to detecting systematic patterns in who accesses treatment and who is left behind.

The scale of the analyzed population matters for the credibility of the findings. With more than a quarter of a million Finnish adults in the study cohort, even relatively small differences in medication uptake between social groups become statistically detectable, and the results are far less likely to be distorted by random variation. Small clinical studies, which typically follow a few hundred patients at specialized obesity clinics, capture only the narrow slice of people who reach tertiary care. A register study, by contrast, observes the full pipeline, from primary care prescriptions through pharmacy dispensing records, and therefore reflects everyday clinical practice rather than the highly selected environment of academic weight-management centers.

Why should the distribution of anti-obesity medication be socially patterned at all? In principle, obesity is not distributed evenly across society in the first place. Decades of epidemiological research, particularly in high-income countries, have consistently shown that obesity prevalence is inversely associated with socioeconomic position: people with lower levels of education and income carry a higher burden of obesity in many populations. If treatment followed need, one would therefore expect anti-obesity medications to be prescribed at least as often, and possibly more often, to people from disadvantaged backgrounds. Whether that is actually the case is the empirical question at the heart of the Finnish register study.

The answer is far from guaranteed, because multiple forces pull access in different directions. On one side sit barriers that tend to concentrate among socioeconomically disadvantaged groups: out-of-pocket medication costs, the ability to navigate healthcare systems, geographic distance from providers who prescribe these drugs, and the time and flexibility required for the frequent follow-up appointments that anti-obesity pharmacotherapy typically demands. On the other side sit factors that may favor advantaged groups or, in some contexts, disadvantage them differently, including physician prescribing preferences, awareness of and demand for newer therapies, and insurance or reimbursement structures that determine how much of the medication price each patient must shoulder.

Anti-obesity pharmacotherapy is also a moving target, and this temporal dimension shapes any register analysis. Older agents, such as orlistat, which acts by inhibiting intestinal fat absorption, and older noradrenergic appetite suppressants, have been joined in recent years by glucagon-like peptide-1 receptor agonists originally developed for type 2 diabetes and subsequently approved for chronic weight management. These newer agents have demonstrated substantially greater average weight loss in randomized trials, but they are also expensive, administered by weekly injection, and often subject to reimbursement restrictions and supply shortages. The social profile of who uses anti-obesity medications is therefore not static; it evolves as the drug landscape, the regulatory environment and public attention to obesity treatment change.

Register data allow researchers to trace these patterns across the entire adult population, stratifying medication use by sex, age, education, income, employment and family circumstances. This multidimensional approach is important because socioeconomic position is not a single variable. Education captures early-life and cognitive resources, income captures current material means, and employment captures attachment to institutions that shape healthcare access. Different dimensions can point in different directions: for instance, medication use might rise with income while showing a different gradient with age or family status. Only a sufficiently large and richly linked dataset can disentangle these overlapping gradients, which is precisely the analytical opportunity afforded by the Finnish registers.

Finland offers a particularly informative setting for this kind of inquiry. Like its Nordic neighbors, it provides tax-funded healthcare to all residents, which softens but does not eliminate the role of purchasing power in treatment access. Prescription medications in Finland are subject to a tiered reimbursement system administered through the national health insurance scheme, and anti-obesity drugs have historically faced strict limits on reimbursement, leaving many patients to pay substantial costs out of pocket. Primary health centers deliver most routine care, while referral pathways govern access to specialized obesity treatment. How these institutional arrangements translate into equitable or inequitable access is exactly the sort of question that register linkage can address with a precision unattainable in most other countries.

The stakes of the question extend well beyond Finland. Health systems worldwide are confronting an unprecedented surge in demand for anti-obesity medications, driven both by rising obesity prevalence and by the demonstrated efficacy of newer agents. Supply constraints, insurance coverage debates and clinical guideline decisions all hinge on assumptions about who benefits from and who deserves access to these therapies. If real-world uptake is systematically skewed by education, income or demography, then the newest and most effective obesity treatments risk widening existing health inequalities rather than narrowing them, echoing patterns previously documented for bariatric surgery, where uptake has often been concentrated among groups that are urban, insured and socioeconomically advantaged despite obesity being more prevalent elsewhere.

For researchers, the Finnish register study of 282,307 adults provides a template for monitoring this emerging therapeutic landscape systematically. For clinicians and policymakers, it underscores that the effectiveness of anti-obesity medications in populations depends not only on their performance in randomized trials but on whether the people who need them most actually receive them. As new agents enter the market and reimbursement policies are revised, continued surveillance of sociodemographic and socioeconomic gradients in medication use will be essential to ensure that the pharmacological revolution in obesity treatment reaches all segments of society rather than only those already best positioned to seize it.

Subject of Research: Sociodemographic and socioeconomic differences in anti-obesity medication use among Finnish adults

Article Title: Sociodemographic and socioeconomic differences in the use of anti-obesity medications: a register study among 282,307 Finnish adults

Article References: Valkonen, J., Svärd, A. C., Roos, E., Joki, A., Kouvonen, A., & Lallukka, T. (2026). Sociodemographic and socioeconomic differences in the use of anti-obesity medications: a register study among 282,307 Finnish adults. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02213-0

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02213-0

Keywords: anti-obesity medications, socioeconomic differences, register study, Finland, obesity treatment, health inequality, pharmacotherapy, prescription drugs, obesity epidemiology, healthcare access, Sociodemographic, socioeconomic